Cann started coverage on shares of Crispr Theraptc (NASDAQ:CRSP) in a research note released on Monday, July 17th, The Fly reports. The brokerage issued a market perform rating on the stock.
A number of other brokerages have also issued reports on CRSP. SunTrust Banks, Inc. started coverage on shares of Crispr Theraptc in a report on Thursday, July 13th. They set a hold rating and a $16.00 price objective for the company. Chardan Capital began coverage on shares of Crispr Theraptc in a report on Monday, March 27th. They set a buy rating and a $23.50 price objective for the company. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $21.92.
Crispr Theraptc (CRSP) traded up 7.98% on Monday, hitting $19.22. 577,867 shares of the company were exchanged. The stock’s market capitalization is $766.78 million. Crispr Theraptc has a 52 week low of $11.63 and a 52 week high of $25.00. The company has a 50 day moving average price of $17.08 and a 200-day moving average price of $17.49.
Crispr Theraptc (NASDAQ:CRSP) last announced its quarterly earnings data on Thursday, August 10th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.06. Crispr Theraptc had a negative net margin of 406.61% and a negative return on equity of 53.86%. The business had revenue of $3.60 million during the quarter, compared to analyst estimates of $3.29 million. Crispr Theraptc’s revenue for the quarter was up 350.0% on a year-over-year basis. On average, equities analysts expect that Crispr Theraptc will post ($2.48) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This report was published by BNB Daily and is the sole property of of BNB Daily. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.baseball-news-blog.com/2017/08/14/crispr-theraptc-crsp-now-covered-by-cann-updated-updated-updated.html.
In other news, CEO Rodger Novak sold 3,650 shares of the firm’s stock in a transaction on Tuesday, May 30th. The stock was sold at an average price of $15.02, for a total transaction of $54,823.00. Following the transaction, the chief executive officer now owns 1,218,655 shares in the company, valued at $18,304,198.10. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Kurt Von Emster sold 35,473 shares of the firm’s stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $18.63, for a total value of $660,861.99. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 543,814 shares of company stock valued at $9,232,047. Corporate insiders own 39.98% of the company’s stock.
A number of institutional investors have recently bought and sold shares of CRSP. Wellington Management Group LLP raised its position in Crispr Theraptc by 0.4% in the first quarter. Wellington Management Group LLP now owns 747,450 shares of the company’s stock valued at $16,272,000 after buying an additional 3,070 shares during the period. Monashee Investment Management LLC raised its position in Crispr Theraptc by 208.7% in the first quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock valued at $473,000 after buying an additional 15,000 shares during the period. Paulson & CO. Inc. bought a new position in Crispr Theraptc during the first quarter valued at about $1,099,000. Credit Suisse AG bought a new position in Crispr Theraptc during the first quarter valued at about $1,742,000. Finally, IHT Wealth Management LLC bought a new position in Crispr Theraptc during the first quarter valued at about $110,000. Institutional investors own 24.08% of the company’s stock.
About Crispr Theraptc
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with MarketBeat.com's FREE daily email newsletter.